- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Concord Biotech Limited — Important, 02-06-2026: Updates
02-06-2026 | 04:41 pm
02-06-2026 | 04:41 pm
Concord Biotech secured USFDA approval for Mycophenolate Mofetil oral suspension, an immunosuppressant. This product targets a US market estimated at US$ 30 million (approx ₹249 Cr), boosting the company's offerings and growth strategy.
No comments yet. Be the first to comment!